ERBB2 and breast carcinoma: However, four cycles of weekly PH (paclitaxel and trastuzumab) and TCtxH (docetaxel, cyclophosphamide and trastuzumab) were both de-escalating anti-HER2 regimens with good long-term outcomes in early-stage breast cancer patients in the adjuvant setting (25, 26).